• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为血管紧张素II - AT1受体拮抗剂的取代苯并咪唑衍生物的3D定量构效关系研究

3D QSAR studies on substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonist.

作者信息

Vyas Vivek K, Ghate Manjunath, Chintha Chetan, Patel Paresh

机构信息

Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, S.G. Highway, Charodi, Ahmedabad 382 481 Gujarat, India.

出版信息

Curr Comput Aided Drug Des. 2013 Sep;9(3):433-45. doi: 10.2174/15734099113099990028.

DOI:10.2174/15734099113099990028
PMID:24010938
Abstract

This study investigated 3D quantitative structure-activity relationships (QSAR) for a range of substituted benzimidazole derivatives as AngII-AT1 receptor antagonists by comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA). The alignment strategy was used for these compounds by means of Distill function defined in SYBYL X 1.2. The best CoMFA and CoMSIA models were obtained for the training set compounds was statistically significant with leave-one-out (LOO) validation correlation coefficient (q²) of 0.613 and 0.622, cross validated coefficient (r²cv) of 0.617 and 0.607, respectively and conventional coefficient (r²ncv) of 0.886 and 0.859, respectively. Both the models were validated by a test set of 18 compounds giving satisfactory predicted correlation coefficient (r²pred) of 0.714 and 0.549 for CoMFA and CoMSIA models, respectively. Generated 3D QSAR models were used for the prediction of pIC50 of an external dataset of 10 compounds for predictive validation, which gave conventional r² of 0.893 for CoMFA model, and 0.774 for CoMSIA model. We identified some key features in substituted benzimidazole derivatives, such as the importance of lipophilicity and H-bonding at 2- and 5, 6, 7- position of benzimidazole ring, respectively, for good antagonistic activity. CoMFA and CoMSIA models generated in this work provide useful information for the design of new compounds and helped in prediction of antagonistic activity.

摘要

本研究通过比较分子场分析(CoMFA)和比较分子相似性指数(CoMSIA)研究了一系列取代苯并咪唑衍生物作为血管紧张素II - AT1受体拮抗剂的三维定量构效关系(QSAR)。借助SYBYL X 1.2中定义的Distill函数对这些化合物进行比对策略。训练集化合物获得的最佳CoMFA和CoMSIA模型具有统计学意义,留一法(LOO)验证相关系数(q²)分别为0.613和0.622,交叉验证系数(r²cv)分别为0.617和0.607,常规系数(r²ncv)分别为0.886和0.859。两个模型均通过18种化合物的测试集进行验证,CoMFA和CoMSIA模型的预测相关系数(r²pred)分别为0.714和0.549,令人满意。生成的三维QSAR模型用于预测10种化合物外部数据集的pIC50以进行预测验证,CoMFA模型的常规r²为0.893,CoMSIA模型的常规r²为0.774。我们确定了取代苯并咪唑衍生物中的一些关键特征,例如亲脂性以及分别在苯并咪唑环的2位和5、6、7位的氢键对于良好拮抗活性的重要性。本研究中生成的CoMFA和CoMSIA模型为新化合物的设计提供了有用信息,并有助于预测拮抗活性。

相似文献

1
3D QSAR studies on substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonist.作为血管紧张素II - AT1受体拮抗剂的取代苯并咪唑衍生物的3D定量构效关系研究
Curr Comput Aided Drug Des. 2013 Sep;9(3):433-45. doi: 10.2174/15734099113099990028.
2
Design, synthesis, pharmacological evaluation and in silico ADMET prediction of novel substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonists based on predictive 3D QSAR models.基于预测性3D QSAR模型的新型取代苯并咪唑衍生物作为血管紧张素II - AT1受体拮抗剂的设计、合成、药理评价及计算机辅助ADMET预测
SAR QSAR Environ Res. 2014;25(2):117-46. doi: 10.1080/1062936X.2013.868825. Epub 2014 Mar 5.
3
Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.CRTh2受体拮抗剂的计算分析:基于配体的比较分子场分析和比较分子相似性指数分析方法
Comput Biol Chem. 2015 Jun;56:109-21. doi: 10.1016/j.compbiolchem.2015.04.007. Epub 2015 Apr 20.
4
3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors.作为丙型肝炎病毒NS5B聚合酶抑制剂的苯并咪唑衍生物的3D QSAR和分子对接研究
J Chem Inf Model. 2008 Jan;48(1):42-55. doi: 10.1021/ci700266z. Epub 2007 Dec 13.
5
CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists.血管紧张素(AT1)受体拮抗剂的比较分子力场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)研究
J Mol Model. 2002 Oct;8(10):290-301. doi: 10.1007/s00894-002-0097-6. Epub 2002 Oct 2.
6
Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of some benzimidazole derivatives with trichomonicidal activity.一些具有杀 Trichomonas 活性的苯并咪唑衍生物的比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)。
Eur J Med Chem. 2011 Aug;46(8):3499-508. doi: 10.1016/j.ejmech.2011.05.016. Epub 2011 May 13.
7
QSAR studies on 3-(4-biphenylmethyl) 4, 5-dihydro-4-oxo-3H-imidazo [4, 5-c] Pyridine derivatives as angiotensin II (AT1) receptor antagonist.QSAR 研究 3-(4-联苯基甲基)-4,5-二氢-4-氧代-3H-咪唑并[4,5-c]吡啶衍生物作为血管紧张素 II (AT1) 受体拮抗剂。
Interdiscip Sci. 2015 Jun;7(2):113-28. doi: 10.1007/s12539-015-0005-2. Epub 2015 Jul 28.
8
3D-QSAR studies on CCR2B receptor antagonists: Insight into the structural requirements of (R)-3-aminopyrrolidine series of molecules based on CoMFA/CoMSIA models.CCR2B受体拮抗剂的3D-QSAR研究:基于CoMFA/CoMSIA模型深入了解(R)-3-氨基吡咯烷系列分子的结构要求。
J Pharm Bioallied Sci. 2012 Apr;4(2):123-33. doi: 10.4103/0975-7406.94813.
9
Discovery of Potent Antihypertensive Ligands Substituted Imidazolyl Biphenyl Sulfonylureas Analogs as Angiotensin II AT1 Receptor Antagonists by Molecular Modelling Studies.通过分子模拟研究发现具有强效降压作用的取代咪唑基联苯磺酰脲类血管紧张素 II AT1 受体拮抗剂配体。
Interdiscip Sci. 2015 Sep;7(3):221-32. doi: 10.1007/s12539-015-0006-1. Epub 2015 Jul 19.
10
3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) and molecular docking study of thienopyrimidine and thienopyridine derivatives to explore structural requirements for aurora-B kinase inhibition.噻吩并嘧啶和噻吩并吡啶衍生物的3D-QSAR(比较分子场分析、比较分子场分析-随机梯度、比较分子相似性指数分析)及分子对接研究,以探索极光-B激酶抑制的结构要求。
Eur J Pharm Sci. 2015 Nov 15;79:1-12. doi: 10.1016/j.ejps.2015.08.017. Epub 2015 Sep 4.

引用本文的文献

1
Exploration of multifaceted molecular mechanism of angiotensin-converting enzyme 2 (ACE2) in pathogenesis of various diseases.血管紧张素转换酶2(ACE2)在各种疾病发病机制中的多方面分子机制探索。
Heliyon. 2023 Apr 20;9(5):e15644. doi: 10.1016/j.heliyon.2023.e15644. eCollection 2023 May.